Quoin Pharmaceuticals Ltd DRC (QNRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Quoin Pharmaceuticals Ltd DRC (QNRX) has a cash flow conversion efficiency ratio of 1.832x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.23 Million) by net assets ($-1.21 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Quoin Pharmaceuticals Ltd DRC - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Quoin Pharmaceuticals Ltd DRC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Quoin Pharmaceuticals Ltd DRC balance sheet liabilities for a breakdown of total debt and financial obligations.
Quoin Pharmaceuticals Ltd DRC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Quoin Pharmaceuticals Ltd DRC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tonkens Agrar AG
XETRA:GTK
|
-0.032x |
|
SONOKONG Co. Ltd
KQ:066910
|
-0.216x |
|
SaveLend Group AB
ST:YIELD
|
0.057x |
|
Adcore Inc
TO:ADCO
|
0.406x |
|
Pharmena S.A.
WAR:PHR
|
-0.078x |
|
ERWE Immobilien AG
F:ERWE
|
-0.040x |
|
Marine Petroleum Trust
NASDAQ:MARPS
|
-1.106x |
|
Baru Gold Corp
V:BARU
|
-0.166x |
Annual Cash Flow Conversion Efficiency for Quoin Pharmaceuticals Ltd DRC (2015–2024)
The table below shows the annual cash flow conversion efficiency of Quoin Pharmaceuticals Ltd DRC from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see Quoin Pharmaceuticals Ltd DRC stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $9.20 Million | $-7.86 Million | -0.854x | +38.52% |
| 2023-12-31 | $5.66 Million | $-7.86 Million | -1.388x | -21.27% |
| 2022-12-31 | $7.41 Million | $-8.48 Million | -1.145x | +86.85% |
| 2021-12-31 | $657.03K | $-5.72 Million | -8.706x | -4397.13% |
| 2020-12-31 | $-6.61 Million | $-1.34 Million | 0.203x | +115.25% |
| 2019-12-31 | $4.30 Million | $-5.71 Million | -1.329x | +24.69% |
| 2018-12-31 | $3.73 Million | $-6.57 Million | -1.764x | -92.44% |
| 2017-12-31 | $5.43 Million | $-4.98 Million | -0.917x | -80.15% |
| 2016-12-31 | $7.40 Million | $-3.77 Million | -0.509x | +30.78% |
| 2015-12-31 | $2.70 Million | $-1.98 Million | -0.735x | -- |
About Quoin Pharmaceuticals Ltd DRC
Quoin Pharmaceuticals, Ltd., a late stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). It also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat Net… Read more